Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Oncol
Huvudupphovsmän: Zhu, Yingying, Jia, Ran, Shao, Yang W., Zhu, Liuqing, Ou, Qiuxiang, Yu, Man, Wu, Xue, Zhang, Yanbei
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2020
Ämnen:
Oncology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7411253/
https://ncbi.nlm.nih.gov/pubmed/32850382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.01259
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk